Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 3/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.60 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 7/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967655 | 0.89 | FFAR1 (0.59) | PARP15PARP10PARP14MAOBFFAR1 | |
| SCHEMBL3969644 | 0.86 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL1067948 | 0.86 | MAOB (0.65) | PARP10MAOBMAOASCN9A | |
| SCHEMBL5681586 | 0.80 | PARP15 (0.50) | PARP15PARP10PARP14MAOBFFAR1 | |
| SCHEMBL3971405 | 0.79 | NPC1 (0.56) | MAOBMAOANPC1RAB9A | |
| SCHEMBL3064569 | 0.79 | MAOB (0.58) | PARP10MAOBMAOASCN9A | |
| SCHEMBL4557098 | 0.79 | CA1 (0.39) | PARP15PARP10PARP14ALDH1A1MMP2 | |
| SCHEMBL3967618 | 0.78 | PARP15 (0.59) | PARP15PARP10PARP14MAOBFFAR1 | |
| SCHEMBL921429 | 0.77 | NPC1 (0.60) | MAOBNPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL8434265 | 0.77 | PARP15 (0.58) | PARP15PARP10PARP14MAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102274517-A | Methods for treatment of parkinson's disease | — | 2011-12-14 | — | — | CN | claimed |
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | claimed |
| EP-0842143-B3 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2009-02-18 | — | — | EP | claimed |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-04-26 | — | — | US | claimed |
| CN-1771030-A | Methods of treating Parkinson's disease | NEWRON PHARMACEUTICALS INC (IT) | 2006-05-10 | — | — | CN | claimed |
| EP-1613296-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | Newron Pharmaceuticals S.p.A. (IT) | 2006-01-11 | — | — | EP | claimed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | claimed |
| EP-0842143-B1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2001-06-13 | — | — | EP | claimed |
| US-5945454-A | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | PHARMACIA & UPJOHN, S.P.A. (IT) | 1999-08-31 | — | — | US | claimed |
| EP-0842143-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-05-20 | — | — | EP | claimed |
| WO-1997005102-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-02-13 | — | — | WO | claimed |
| US-9492410-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2016-11-15 | — | — | US | disclosed |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| US-8901176-B2 | Methods for treatment of Parkinson's disease | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2014-12-02 | — | — | US | disclosed |
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS S.P.A (IT) | 2013-02-28 | — | — | US | disclosed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | disclosed |
| EP-0842143-B1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2001-06-13 | — | — | EP | disclosed |
| US-5945454-A | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | PHARMACIA & UPJOHN, S.P.A. (IT) | 1999-08-31 | — | — | US | disclosed |
| EP-0842143-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997005102-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053368-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | MAOB, MAOA, SNCA | PARP15 416/4885PARP10 771/4885PARP14 661/4885 |
| US-20070093495-A1 | Methods for treatment of parkinson's disease | MAOB, MAOA, SNCA | PARP15 416/4885PARP10 771/4885PARP14 661/4885 |
| US-20150150833-A1 | Methods For Treatment of Parkinson's Disease | MAOB, MAOA, SNCA | PARP15 416/4885PARP10 771/4885PARP14 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.